Han Sol Lee

Han Sol Lee

Auto-generated profile, based on publicly available information

Han Sol Lee

Daewoong Pharmaceutical Co., Ltd., Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Nutrition Research and Practice
Verified
Journal Article
Open access
PDF file
HLHan Sol Lee
Han Sol Lee
EBEun Young Bae
Eun Young Bae
SLSun Yung Ly
Sun Yung Ly
Lee HS, et al. Nutr Res Pract. 2023 Oct;17(5):855-869. https://doi.org/10.4162/nrp.2023.17.5.855

31 August 2025 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
YLYoung Sang Lyu
Young Sang Lyu
HLHansol Lee
Hansol Lee
KKKyung-Soo Kim
Kyung-Soo Kim
SHSangmo Hong
Sangmo Hong
Cheol-Young ParkCheol-Young Park
Cheol-Young Park
The metabolic benefits of sodium-glucose co-transporter 2 inhibitors in clinical application are well established; however, there is dearth of knowledge on their impact on adipokine regulation. This study investigated the effect of enavogliflozin on adiponectin and leptin in patients with type 2 diabetes. This secondary analysis of a phase III randomized, double-blind, placebo-controlled trial evaluated changes in serum adiponectin and leptin over 24 weeks. Analysis of covariance was used with baseline values and weight change as covariates to examine whether the effects of enavogliflozin persisted after adjusting for weight change. Correlations between adipokine changes and key metabolic parameters were also assessed. Over the 24 weeks, the enavogliflozin group showed increased adiponectin levels with a least squares (LS) mean difference of 0.98 mg/L compared with the placebo group, while leptin levels showed a significant decrease with an LS mean difference of −2.99 µg/L. Enavogliflozin significantly reduced leptin levels over 24 weeks after adjusting for weight change; however, adiponectin changes were not significant after adjusting for weight change. Adiponectin levels significantly increased across weight loss categories, but leptin showed no significant differences. Leptin changes over 24 weeks significantly were positively correlated with changes in homeostasis model assessment of insulin resistance and homeostasis model assessment of β-cell function but significantly negatively correlated with changes in serum ketone and urinary glucose-to-creatinine ratio. Enavogliflozin treatment decreased leptin over 24 weeks in patients with type 2 diabetes, and this effect remained significant after adjusting for weight change, suggesting an improved adipokine profile. Reductions in leptin were also associated with improvements in insulin resistance and increases in serum ketone levels. These results highlight enavogliflozin as a potential treatment beyond glycemic control, offering additional benefits in managing metabolic dysregulation associated with type 2 diabetes. Not applicable (post hoc analysis).